• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 25th March 2012

Can lessons from valuing health be useful in valuing development aid?

Measuring and evaluating the impact of development aid is a perennial challenge. Various approaches have been tried. Since many have been aimed at donor needs and objectives, whether or not they adequately reflect improvement in the daily lives of the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Measuring and evaluating the impact of development aid is a perennial challenge. Various approaches have been tried. Since many have been aimed at donor needs and objectives, whether or not they adequately reflect improvement in the daily lives of the target population is open to question.

Measuring and evaluating the impact of development aid is a perennial challenge. Various approaches have been tried.  Since many have been aimed at donor needs and objectives, whether or not they adequately reflect improvement in the daily lives of the target population is open to question. The UK’s Overseas Development Institute (ODI) recently held a workshop on measuring and valuing wellbeing in health and development, in part to explore how experience in the health sector might help guide the creation of measurements for development efforts.

As the basis for discussion, OHE's Nancy Devlin co-authored a paper with Claire Melamed of the ODI and John Appleby of the King’s Fund, now available on the ODI’s website: 'Valuing development': Could approaches to measuring outcomes in health help make development more accountable? 'The challenge,' according to the authors, 'and the research question, is to establish whether we can devise a way of measuring outcomes, based on poor people's own values, that strikes the right balance between reasonable representation of reality and usability by policy makers'.

In the health sector, it is increasingly possible to express actual or expected outcomes using summary numeric measures based on patients’ experiences and/or public preferences — for example through QALYs and patient reported outcomes measures, such as the EQ-5D. The authors explain how these methods have been devised, tested, tweaked and used as the basis of resource allocation decisions.  They note that many of the principles that apply in the appropriate design and use of health measures could be applicable to efforts to devise better measures for the effects of development aid.

Challenges in development measurement are likely to be somewhat different in kind and/or degree than those for health.  For example, the objective of health care quite clearly is a long life lived in as good health as possible.  Measuring the 'right' thing in the case of development requires understanding what poor people in developing countries value, which will be more than a single outcome.  The authors note, however, that 'it is striking that participatory exercises of different types reveal a number of strong similarities in the way that people understand poverty and development in different countries and contexts'. Highly valued are physical health and strength, physical safety and security, economic security, and good community relationships.  The relative value given to each of these, of course, will vary across and within countries, across subpopulations, among sectors, and over time.  Whether people become used to sustained deprivation and adapt their preferences accordingly also is a matter of some debate. Devising a single measure, then, that can allow comparison across countries, as well as within countries, will be a serious methodological challenge.  The kind of systematic, iterative approach used in health, however, can help work through the critical methodological issues.

Assuming that the challenges are met successfully, the authors identify the advantages of using a generic outcome measure for development aid as including the following.

  • Consistent, comparable, reliable measurement can offer a method for comparing the impacts of projects across different sectors — or even within the same sector for projects with slightly different objectives. This could help identify what works and what doesn't, much as a randomised clinical trial does in medicine.
  • Outcome measures could be used to compare changes in the whole population or in sectors over time, identifying when aid has been most, and least, successful.
  • In practical application in decision-making, measurement can help donors and others 'ensure that the views and preferences of poor people feed directly into assessments of value for money and development spending'.
  • A standard set of development outcomes and a methodology for exploring the weights attached to them could allow systematic comparisons of priorities across different groups.  Understanding the different weights attached to various outcomes by, for example, population subgroups, local communities, donors, and government officials, could help ensure that dialogue about the value of efforts are based on real evidence about what 'value' means for different groups and stakeholders.

Of course, the ultimate goal of learning from the experiences of measurement in health care is creating a useful tool for making choices about development aid.  A straightforward metric is important in helping policy makers bridge the gap between the complex realities faced by the poor and the need for simplicity in decision-making.

Download: Melamed, C., Devlin, N. and Appleby, J. (2012) 'Valuing development': Could approaches to measuring outcomes in health help make development more accountable?  Research reports and studies. London: Overseas Development Institute.

  • Emerging Markets
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!